Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

The CentiMarker project : Standardizing quantitative Alzheimer's disease fluid biomarkers for biologic interpretation

Wang, Guoqiao ; Li, Yan LU ; Xiong, Chengjie ; Cao, Yuchen ; Schindler, Suzanne E. ; McDade, Eric ; Blennow, Kaj LU ; Hansson, Oskar LU orcid ; Dage, Jeffrey L. and Jack, Clifford R. , et al. (2025) In Alzheimer's and Dementia 21(4).
Abstract

INTRODUCTION: Biomarkers play a crucial role in understanding Alzheimer's disease (AD) pathogenesis and treatment effects. However, comparing biomarker measures without standardization and appreciating their magnitude relative to the disease can be challenging. METHODS: To address this issue, we propose the CentiMarker approach, similar to Centiloid, which provides a standardized scale between normal (0) and nearly maximum abnormal AD (100) ranges. We applied this scale to cerebrospinal fluid (CSF) biomarkers in dominantly inherited AD and sporadic AD cohorts. RESULTS: CentiMarkers facilitated the interpretation of disease abnormality, demonstrating comparable changes and distributions of AD biomarkers across disease stages.... (More)

INTRODUCTION: Biomarkers play a crucial role in understanding Alzheimer's disease (AD) pathogenesis and treatment effects. However, comparing biomarker measures without standardization and appreciating their magnitude relative to the disease can be challenging. METHODS: To address this issue, we propose the CentiMarker approach, similar to Centiloid, which provides a standardized scale between normal (0) and nearly maximum abnormal AD (100) ranges. We applied this scale to cerebrospinal fluid (CSF) biomarkers in dominantly inherited AD and sporadic AD cohorts. RESULTS: CentiMarkers facilitated the interpretation of disease abnormality, demonstrating comparable changes and distributions of AD biomarkers across disease stages. CentiMarkers make the treatment effect more comparable than their original scales across various biomarkers. DISCUSSION: The versatility of CentiMarkers makes it a valuable tool for standardized biomarker comparison in AD research, enabling informed cross-study comparisons and contributing to accelerated therapeutic development. Adoption of the CentiMarker scale could enhance biomarker reporting and advance our understanding of AD. Highlights: Comparing fluid biomarkers without appreciating their magnitude relative to the disease can be challenging. We propose a CentiMarker metric to standardize biomarker measures from normal (0) and nearly maximum abnormal AD (100) ranges. CentiMarkers make the treatment effect more comparable across various biomarkers than when using the original scales.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
author collaboration
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer's disease, biomarker standardization, CentiMarker, fluid biomarker
in
Alzheimer's and Dementia
volume
21
issue
4
article number
e14587
publisher
Wiley
external identifiers
  • scopus:105003408344
  • pmid:40235082
ISSN
1552-5260
DOI
10.1002/alz.14587
language
English
LU publication?
yes
id
e1b5aac9-0c15-4566-8ad1-6444d1041d10
date added to LUP
2025-08-12 10:53:02
date last changed
2025-08-13 03:00:09
@article{e1b5aac9-0c15-4566-8ad1-6444d1041d10,
  abstract     = {{<p>INTRODUCTION: Biomarkers play a crucial role in understanding Alzheimer's disease (AD) pathogenesis and treatment effects. However, comparing biomarker measures without standardization and appreciating their magnitude relative to the disease can be challenging. METHODS: To address this issue, we propose the CentiMarker approach, similar to Centiloid, which provides a standardized scale between normal (0) and nearly maximum abnormal AD (100) ranges. We applied this scale to cerebrospinal fluid (CSF) biomarkers in dominantly inherited AD and sporadic AD cohorts. RESULTS: CentiMarkers facilitated the interpretation of disease abnormality, demonstrating comparable changes and distributions of AD biomarkers across disease stages. CentiMarkers make the treatment effect more comparable than their original scales across various biomarkers. DISCUSSION: The versatility of CentiMarkers makes it a valuable tool for standardized biomarker comparison in AD research, enabling informed cross-study comparisons and contributing to accelerated therapeutic development. Adoption of the CentiMarker scale could enhance biomarker reporting and advance our understanding of AD. Highlights: Comparing fluid biomarkers without appreciating their magnitude relative to the disease can be challenging. We propose a CentiMarker metric to standardize biomarker measures from normal (0) and nearly maximum abnormal AD (100) ranges. CentiMarkers make the treatment effect more comparable across various biomarkers than when using the original scales.</p>}},
  author       = {{Wang, Guoqiao and Li, Yan and Xiong, Chengjie and Cao, Yuchen and Schindler, Suzanne E. and McDade, Eric and Blennow, Kaj and Hansson, Oskar and Dage, Jeffrey L. and Jack, Clifford R. and Teunissen, Charlotte E. and Shaw, Leslie M. and Zetterberg, Henrik and Ibanez, Laura and Timsina, Jigyasha and Carlos, Cruchaga and Bateman, Randall J.}},
  issn         = {{1552-5260}},
  keywords     = {{Alzheimer's disease; biomarker standardization; CentiMarker; fluid biomarker}},
  language     = {{eng}},
  number       = {{4}},
  publisher    = {{Wiley}},
  series       = {{Alzheimer's and Dementia}},
  title        = {{The CentiMarker project : Standardizing quantitative Alzheimer's disease fluid biomarkers for biologic interpretation}},
  url          = {{http://dx.doi.org/10.1002/alz.14587}},
  doi          = {{10.1002/alz.14587}},
  volume       = {{21}},
  year         = {{2025}},
}